MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

CRL · NYSE

Charles River Laboratories International, Inc.

Health Care · Biotechnology: Commercial Physical & Biological Resarch

Reference price$240.43As of Jul 28, 2026
Market capitalization$11.58B
52-week range$144.26–$238.85
S&P 500 portfolio weight0.02%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$213.00-11.4% vs. reference
Average$230.20-4.3% vs. reference
High$265.00+10.2% vs. reference
10 Buy2 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportAug 5, 2026Jun 2026
Consensus EPS$2.726 estimates
Expected range$2.69–$2.79Low to high EPS
Dec 2026$11.05Street EPS consensus
Dec 2027$12.11Street EPS consensus
Dec 2028$13.17Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 27, 2025.

MetricCurrentPrior
Revenue-0.9% YoY$4.02B$4.05B
Operating income$0.03B$0.23B
Net income($0.14B)$0.02B
Operating cash flow$0.74B$0.73B
Capital expenditures($0.22B)($0.23B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

HCA Q2 Earnings Beat on Strong Admissions, 2026 Outlook Revised

Zacks

What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now?

Zacks

Abbott Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-market

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.